At the news
? BULLISHIMPACT 8/10 8-K filed May 14, 2026 at 08:45 ET
Biogen completed its acquisition of Apellis Pharmaceuticals on May 14, 2026, through a tender offer and subsequent merger. Apellis stockholders received $41.00 per share in cash plus one contingent value right (CVR) per share, with potential milestone payments of up to $4.00 per CVR tied to SYFOVRE sales targets. The deal valued at approximately $5.3 billion, and APLS common stock has been delisted from Nasdaq, with the company now a wholly owned subsidiary of Biogen.
- Biogen completed acquisition of Apellis for $41.00 per share in cash plus one CVR per share (up to $4.00 additional per CVR tied to SYFOVRE sales milestones).
- Total deal value approximately $5.3 billion, excluding potential CVR payments.
- 105,687,831 shares (82.4% of outstanding) were validly tendered in the offer.
- CVR milestones: $2.00 per CVR if SYFOVRE annual net sales reach $1.5B in 2027-2030; $2.00 per CVR if sales reach $2.0B in 2027-2031 (or $4.00 if first milestone missed but second achieved in 2031).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access